University Research Park (URP), University of Wisconsin Madison, Research and Technology Park, Early Stage Incubator, Technology Transfer, Tech Transfer, Research Park

Home | Contact Us

New ‘urban research park’ offers jolt of electricity to Madison high-tech startups
August 4, 2008
After three decades of almost exponential commercial growth on Madison's west side, the University Research Park (URP) will pursue an opportunity to sink roots downtown with an innovative "urban research park" targeting high-technology entrepreneurs.

...............................................

University Research Park publishes "The First Fifteen Years: 1984-1999", a retrospective about the award winning research park
March 7, 2008 - MADISON, Wis.
The publication, written by Arthur Hove leads readers through the park's first 15 years, spotlighting the innovative efforts that brought the park from idea to reality.

Bizjournals Study Declares Madison Smartest City
April 2008
A new bizjournals study that ranks the brainpower levels of America's 100 largest metropolitan areas finds that Madison, Wis., leads the list.

Wisconsin's sights are set on Earth-friendly tourism
USA Today | September 07
The Aldo Leopold Legacy Center is just one example of some 100 lodgings, restaurants, attractions and other tourism-related businesses to be certified by Travel Green Wisconsin, a statewide initiative launched earlier this year that's the first of its kind in the USA.

25 Best Cities: Kiplinger / Richard Florida Rankings
June 2007
Madison is picked as one of top 25 cities with a large creative class—a population that fuels cultural and economic vitality—that are suited for people in different life stages.

Cellular Dynamics International, Inc.
Cellular Dynamics International Inc. (CDI) is a privately held drug screening company founded by the scientific team of Drs. James Thomson, Craig January and Tim Kamp in partnership with Tactics II Ventures, LLP.

Stemina Biomarker Discovery, Inc.
Stemina’s innovative cell based assays arise from the strategic convergence of two groundbreaking technologies: stem cells and metabolomics. As a result, Stemina discovers and validates small molecules as biomarkers for high throughput drug screening and disease diagnostics in an all human system.